In vivo CAMPATH-1 monoclonal antibodies:
In vivo CAMPATH-1 monoclonal antibodies: A novel mode of therapy for acute graft-versus-host disease
โ
Varadi, Gabor; Or, Reuven; Slavin, Shimon; Nagler, Arnon
๐
Article
๐
1996
๐
John Wiley and Sons
๐
English
โ 205 KB
๐ 2 views
CHOP, COP plui doxorubicin. ,'According to NCI criteria (Cheson el al. 151). (PD) was registered in one patient. Median time to disease progression for patients in PR or SD was 9 months (range, 1-14 months) (Table I). The results of the prehent study, although based on a small number of patients,